PMN
NASDAQ HealthcareProMIS Neurosciences Inc. - Common Shares
Biotechnology
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS, which enables drug discovery through a combination of protein biology, physics, and supercomputing. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's disease; PMN267 for the treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for the treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
�� 市场数据
| 价格 | $13.30 |
|---|---|
| 成交量 | 163,106 |
| 市值 | 119.27M |
| 贝塔系数 | -0.210 |
| RSI（14日） | 69.2 |
| 200日均线 | $11.90 |
| 50日均线 | $11.16 |
| 52周最高 | $39.75 |
| 52周最低 | $6.27 |
| Forward P/E | -5.53 |
| Price / Book | 1.96 |
🎯 投资策略评分
PMN 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (81/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🐋 Institutional Whale (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 PMN in your text
粘贴任何文章、记录或帖子 — 工具将提取 PMN 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-07-16.